PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12292745

A view from the grass roots.

View original source ↗Export metadata ↓

Abstract

A 14-member study team learned firsthand about promotion of family planning and maternal and child health (FP/MCH) in China while in the country during August 17-30, 1997. The self-funded team was headed by JOICFP Chairman Masao Sawaki and included representatives of the public health and preventive health field as well as an official from a Japanese university. The team first traveled to Fangshan District of Beijing where implementation of JOICFP's Integrated Project (IP) began in 1996. A fifth-cycle project area, Fangshan is receiving assistance from IPPF through JOICFP for a period of 3 years. The team moved north to Inner Mongolia Autonomous Region to observe IP activities in Tumud Left Banner of Hohhot City, a second-cycle project area which received support between 1987 and 1989. The third area visited was Yunnan Province in the south, where they observed activities in Jiangchuan County, a third-cycle area which was supported between 1990 and 1992. The comparison between the pilot area and original project areas was rewarding for the team, which noted that activities had continued to expand with support from the people after the 3-year funding period had ceased. In Inner Mongolia, the team noted how parasite control has been effectively used to gain community participation in activities. The project has expanded from 2 towns with a population of 50,000 to cover 19 towns with 343,000 people. In Jiangchuan Country, the IP has expanded from 5 towns with 108,000 people to cover 12 towns with 240,000. Prior to the project launch in 1989, the infant mortality was 60/1000 live births and the hospital delivery rate was 45%. These had improved to reach 23.3/1000 and 87%, respectively, as of 1996.

Explore related subjects

AsiaChinaDelivery of Health CareDeveloping CountriesEvaluation Studies as TopicFamily Planning ServicesAsia, EasternHealthHealth PlanningHealth ServicesMaternal-Child Health CentersOrganization and AdministrationPrimary Health CareProgram DevelopmentDelivery Of Health CareEastern AsiaEvaluationFamily PlanningFamily Planning ProgramsIntegrated ProgramsMaternal-child Health ServicesMonitoringOrganization And AdministrationProgramsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

1997. A view from the grass roots.. https://pubmed.ncbi.nlm.nih.gov/12292745/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Reassortment of Highly Pathogenic Avian Influenza as a Driver for Zoonotic Spillover, Asia.

Highly pathogenic avian influenza H5Nx viruses remain a major zoonotic threat, yet global attention has focused largely on clade 2.3.4.4b, potentially overlooking major changes within long-endemic H5N1 lineages in Asia. Recent reports from South and Southeast Asia describe the emergence of reassortant clade 2.3.2.1 viruses alongside renewed human infections after apparent prolonged epidemiologic stability. Collectively, those events suggest a regional pattern rather than isolated anomalies. In this article, we argue that reassortment, rather than point mutation alone, might be an underrecognized driver of zoonotic risk in endemic H5N1 lineages and is reshaping those lineages. We examine why such events might be underrecognized in settings with entrenched poultry influenza, identify limitations of current surveillance systems, and call for integrated, real-time approaches linking genomic detection with phenotypic assessment across animal and human health sectors to enable timely risk assessment and coordinated public health action.

Asia↗
PubMed2026

Financing and health system capacity for precision medicine in Asia: a six country landscape analysis.

BACKGROUND: Precision medicine (PM) adoption is accelerating across Asia, but implementation remains uneven due to differences in financing, infrastructure, governance, and health-system readiness. OBJECTIVES: To examine how six Asian countries (Singapore, South Korea, China, Malaysia, Thailand, and Indonesia) adopt, finance, and integrate PM technologies, and identify common implementation patterns and challenges. METHODS: A landscape review of peer-reviewed literature, government publications, and HTA reports (2010-2026) was conducted, supplemented by stakeholder consultations. PM applications were grouped into public health screening (hereditary breast and ovarian cancer [HBOC] and familial hypercholesterolemia [FH] cascade testing), next-generation sequencing (NGS) applications (rare diseases, oncology, pharmacogenomics), and AI-enabled PM. Evidence was synthesized across access, awareness, reimbursement, and implementation. RESULTS: Public health genomic screening demonstrated the highest implementation readiness, followed by precision oncology, while rare disease diagnostics remained infrastructure-dependent and pharmacogenomics and AI-enabled PM platforms were at earlier stages. Four readiness profiles emerged: highly aligned systems; reimbursement-constrained systems with strong governance and infrastructure; systems strengthening governance, public financing and infrastructure; and strategy-led systems expanding implementation through pilot programs and referral centers. CONCLUSIONS: PM implementation across Asia remains heterogeneous. The identified readiness profiles highlight governance, financing, and infrastructure priorities for sustainable and equitable PM diffusion.

Asia↗
PubMed2026

Double heterozygous germline pathogenic variants in patients referred to a tertiary cancer genetics clinic in Singapore.

BACKGROUND: The increasing use of multigene panel testing has led to a rise in the identification of double heterozygous (DH) pathogenic variants in cancer patients, although their frequency and clinical relevance remain poorly characterised, particularly in Asian populations. METHODS: We conducted a retrospective review of 5,178 patients referred to a tertiary cancer genetics clinic in Singapore. DH pathogenic variants were defined as the presence of two or more distinct pathogenic or likely pathogenic germline variants identified by multigene panel testing. Clinical, pathological, and family history data were reviewed and analysed using appropriate non-parametric and exact statistical methods. RESULTS: Among 2,802 index patients with available genetic test results, 593 (21.2%) carried at least one pathogenic/likely pathogenic variant. DH pathogenic variants were identified in 21 individuals (0.75%), of which 9 were patients with breast cancer, 10 with non-breast malignancies, and 2 were cancer-free. The frequency of multiple primary cancers was 26.3% in DH variant carriers, 23.3% in single variant carriers, and 16.5% in those with no pathogenic variants. The median ages of first cancer diagnosis were 47, 44, and 48 years. Several DH combinations involved moderate- or low-penetrance genes, and some clinically unsuspected variants were detected only through broad multigene testing. CONCLUSION: DH pathogenic variants represent a rare subgroup that is increasingly detected through multigene panel testing. Their phenotypic expression is variable, and the influence of additional pathogenic variants remains uncertain. Our findings emphasise the need for tailored genetic evaluation and further research to guide evidence-based management for this complex patient population.

Asia↗